Lineage Cell Therapeutics, Inc. (LCTX)
Largest Insider Buys in Sector
LCTX Stock Price History Chart
LCTX Stock Performance
About Lineage Cell Therapeutics, Inc.
Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for the treatment of degenerative diseases in the United States and internationally. The company develops OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an oligodendrocyte progenitor cell therapy that is in Phase I/IIa multicenter clinical trial for the treatment of acute spinal cord injuries; and VAC2, an allogeneic …
Insider Activity of Lineage Cell Therapeutics, Inc.
Over the last 12 months, insiders at Lineage Cell Therapeutics, Inc. have bought $7.13M and sold $0 worth of Lineage Cell Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Lineage Cell Therapeutics, Inc. have bought $3.61M and sold $1.35M worth of stock each year.
Highest buying activity among insiders over the last 12 months: BROADWOOD PARTNERS, L.P. () — $21M. BAILEY DON M (director) — $200,002. Culley Brian M (President and CEO) — $21,000.
The last purchase of 10,500 shares for transaction amount of $9,345 was made by Howe Jill Ann (Chief Financial Officer) on 2024‑08‑16.
List of Insider Buy and Sell Transactions, Lineage Cell Therapeutics, Inc.
| 2024-08-16 | Chief Financial Officer | 10,500 0.0059% | $0.89 | $9,345 | 0.00% | |||
| 2024-05-24 | President and CEO | 10,000 0.0054% | $1.05 | $10,500 | -13.56% | |||
| 2024-02-08 | director | 96,155 0.0563% | $1.04 | $100,001 | -7.41% | |||
| 2024-02-06 | 6.73M 3.9412% | $1.04 | $7M | -9.01% | ||||
| 2023-12-29 | director | 10,000 0.0057% | $1.09 | $10,900 | -4.63% | |||
| 2022-03-31 | President and CEO | 6,400 0.0037% | $1.53 | $9,792 | -11.04% | |||
| 2022-03-28 | 35,000 0.0227% | $1.63 | $57,050 | -7.43% | ||||
| 2022-03-25 | President and CEO | 5,250 0.0029% | $1.38 | $7,245 | -7.43% | |||
| 2022-03-24 | 7,000 0.004% | $1.40 | $9,800 | -4.86% | ||||
| 2022-03-23 | 0 – | $0 | $0 | -0.72% | ||||
| 2021-12-29 | Sale | SVP,Clinical & Medical Affairs | 37,695 0.0227% | $2.45 | $92,438 | -43.21% | ||
| 2021-12-28 | Sale | SVP,Clinical & Medical Affairs | 501,588 0.298% | $2.45 | $1.23M | -43.70% | ||
| 2021-06-29 | Sale | director | 4,720 0.0029% | $2.97 | $14,018 | -29.69% | ||
| 2021-06-29 | Sale | director | 19,142 0.0117% | $2.93 | $56,086 | -29.69% | ||
| 2021-06-28 | Sale | President and CEO | 450,000 0.2743% | $2.87 | $1.29M | -28.72% | ||
| 2021-03-30 | Sale | Sr Director Finance/Controller | 6,000 0.0037% | $2.23 | $13,380 | +6.64% | ||
| 2019-08-15 | 13,146 0.0088% | $0.97 | $12,717 | -4.89% | ||||
| 2019-08-14 | 1,407 0.0009% | $0.98 | $1,379 | -4.35% | ||||
| 2019-08-13 | 10,000 0.0065% | $0.99 | $9,949 | -4.35% | ||||
| 2019-08-13 | President and CEO | 10,000 0.0066% | $1.01 | $10,100 | -4.35% |
Insider Historical Profitability
| BROADWOOD PARTNERS, L.P. | 41666255 22.0647% | $0.60 | 19 | 1 | +10.66% | |
| BAILEY DON M | director | 158801 0.0841% | $0.60 | 1 | 0 | |
| Culley Brian M | President and CEO | 154842 0.082% | $0.60 | 4 | 1 | <0.0001% |
| Howe Jill Ann | Chief Financial Officer | 10500 0.0056% | $0.60 | 1 | 0 | |
| Jayasuriya Anula | director | 10000 0.0053% | $0.60 | 1 | 0 |
Institutional Investor Ownership
| Broadwood Capital Inc | $61.67M | 22.07 | 41.67M | +19.27% | +$9.96M | 4.63 | |
| BlackRock | $12.57M | 4.5 | 8.49M | -0.43% | -$54,912.43 | <0.0001 | |
| The Vanguard Group | $12.39M | 4.43 | 8.37M | -0.13% | -$16,155.68 | <0.0001 | |
| Logos Global Management Lp | $9.25M | 3.31 | 6.25M | New | +$9.25M | 1 | |
| Defender Capital | $7.35M | 2.63 | 4.97M | -0.04% | -$2,960.00 | 2.5 |